Friday, July 17, 2026

U.S. Diplomat Hopes to Revive North-South Korea Relations: Can Trump Be the Peacekeeper?

Jung Chung-rae meets U.S. Chargé d'Affaires Yun, emphasizing the need for U.S. support in inter-Korean peace and relations.

Gold-Backed Financial Products See Massive Growth in South Korea Amid Price Surge

Gold prices surge amid global uncertainty, boosting interest in gold banking and sales in South Korea, with accounts increasing significantly.

Are We Prepared for Space Threats? Exploring South Korea’s Urgent Need for Defense Space Legislation

A policy forum in Seoul discussed urgent defense space legislation amid threats from North Korea to South Korean satellites.

Tag: Samsung Bioepis

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

AI-Powered Antibody Drug Development: Samsung Biologics and Protina’s Game-Changing License Agreement

Samsung Bioepis and Protina sign a licensing agreement to develop AI-designed antibody drugs, aiming for candidates by 2027.

Unlocking Cancer Treatment: Samsung Bioepis Achieves Keytruda Biosimilar Equivalence in Global Trials

Samsung Bioepis' biosimilar SB27 shows equivalence to Keytruda in key clinical trials, enhancing access to cancer immunotherapy.

Samsung Bioepis Launches SBE303: The First ADC Drug Candidate Targeting Nectin-4 in Cancer Trials

Samsung Bioepis has begun Phase 1 trials for its ADC candidate SBE303, targeting solid tumors, set to continue until July 2030.

Samsung Bioepis Expands SB15 Eylea Rival: Licensing Pact Targets Global Markets as Original Drug Hits $10.5B Sales

Samsung Bioepis has secured a licensing deal for its ophthalmic treatment SB15, expanding access in international markets outside the US and Canada.

Samsung Bioepis Taps Harrow to Take Over U.S. Ophthalmic Drug Rights from Biogen

Samsung Bioepis partners with Harrow to sell ophthalmic treatments in the U.S., transferring rights from Biogen by 2025.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.